CTI BioPharma Corp (fka CTIC)

[ThatStockGuy]

Cell Therapeutics spokesman Dan Eramian said many of the key issues raised by FDA staff were addressed in a company summary prepared for the panel.

In the summary, the company said pixantrone worked better than other drugs with 'manageable toxicities.' Twenty percent of patients treated with pixantrone met the study's main goal of having a major decrease in their disease, compared with about 6 percent with a different medicine.